Omeros has been granted a patent for compounds that have MASP-2 inhibitory activity. The patent also covers the compositions and methods of making and using these compounds. GlobalData’s report on Omeros gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Omeros, peptide pharmacophores was a key innovation area identified from patents. Omeros's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11661418B2) discloses a compound with a specific chemical structure (Structure I). The compound can have various substitutions, including a substituted or unsubstituted phenyl group (R'). Additionally, the compound can have different structures for R1, such as a substituted or unsubstituted heteroaryl group. R1 can also be substituted with various substituents, including a substituted heteroaryl group, C(-NH)NHC(-O)OR8, C(-NOC(-O)R8)NH2, C(-NOC(-O)OR8)NH2, and C(-NOH)NH2. In particular, when R1 is substituted with C(-NH)NHC(-O)OR8, R8 can be a substituted or unsubstituted arylalkyl group. Similarly, when R1 is substituted with C(-NOC(-O)R8)NH2, R8 can be an aminylalkyl group, an alkyl group, a haloalkyl group, or a substituted or unsubstituted arylalkyl group.
The compound can also have different possibilities for R2, including hydrogen or C1-C6 alkyl. In one embodiment, R2 is specifically methyl (—CH3). Furthermore, R2 and R3, along with the carbon and nitrogen to which they are attached, can form an optionally substituted 4, 5, or 6 membered heterocyclyl group. R4, on the other hand, can be a substituted or unsubstituted aryl group and can have specific structures. R5a can be alkyl, C(-O)OR6, phosphonalkyl, or (CH2)nC(-O)OR6, with different structures for R5a also mentioned. R5b can be an electron pair or alkyl.
The patent also covers compounds with alternative structures to Structure I. Additionally, it includes a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient. The patent further discloses a method for treating a MASP-2-associated disease or disorder in a subject by administering an effective amount of the compound.
In summary, the granted patent describes a compound with a specific chemical structure and various possible substitutions. It also covers alternative structures, a pharmaceutical composition containing the compound, and a method for treating MASP-2-associated diseases or disorders using the compound.
To know more about GlobalData’s detailed insights on Omeros, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
